Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study

Antoni Sicras-Mainar,1 Juan Carlos Tornero-Tornero,2 Francisco Vargas-Negrín,3 Isabel Lizarraga,4 Aram Sicras-Navarro,1 Javier Rejas-Gutierrez5 1Health Economics and Outcomes Research Department, Atrys Health, Barcelona, Spain; 2Department of Anesthesiology, Hospital Clínico Universitario of Valenci...

Full description

Bibliographic Details
Main Authors: Sicras-Mainar A, Tornero-Tornero JC, Vargas-Negrín F, Lizarraga I, Sicras-Navarro A, Rejas-Gutierrez J
Format: Article
Language:English
Published: Dove Medical Press 2022-03-01
Series:Open Access Rheumatology: Research and Reviews
Subjects:
Online Access:https://www.dovepress.com/sick-leave-and-costs-in-active-workers-with-chronic-osteoarthritis-pai-peer-reviewed-fulltext-article-OARRR
_version_ 1828774416244277248
author Sicras-Mainar A
Tornero-Tornero JC
Vargas-Negrín F
Lizarraga I
Sicras-Navarro A
Rejas-Gutierrez J
author_facet Sicras-Mainar A
Tornero-Tornero JC
Vargas-Negrín F
Lizarraga I
Sicras-Navarro A
Rejas-Gutierrez J
author_sort Sicras-Mainar A
collection DOAJ
description Antoni Sicras-Mainar,1 Juan Carlos Tornero-Tornero,2 Francisco Vargas-Negrín,3 Isabel Lizarraga,4 Aram Sicras-Navarro,1 Javier Rejas-Gutierrez5 1Health Economics and Outcomes Research Department, Atrys Health, Barcelona, Spain; 2Department of Anesthesiology, Hospital Clínico Universitario of Valencia, Valencia, Spain; 3Healthcare Center Dr. Guigou, Canary Islands Health Service, Tenerife, Spain; 4Medical Department, Pfizer, SLU, Alcobendas, Madrid, Spain; 5Health Economics and Outcomes Research Department, Pfizer, SLU, Alcobendas, Madrid, SpainCorrespondence: Antoni Sicras-Mainar, Health Economics and Outcomes Research Department, Atrys Health, C/ Provença 392, bajos, Barcelona, 08025, Spain, Tel +34 934 581 561, Fax +34 93 458 73 03, Email ansicras@atryshealth.comPurpose: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain.Patients and Methods: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥ 18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥ 1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months.Results: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p< 0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (− 1.2 points; − 4.0%, p< 0.001). The cost of sick leave was € 2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p< 0.05 in all associations).Conclusion: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society.Keywords: analgesics, arthritis, disability, sick days, observational study
first_indexed 2024-12-11T15:20:41Z
format Article
id doaj.art-3f1b627555af414391bc8470c1b11451
institution Directory Open Access Journal
issn 1179-156X
language English
last_indexed 2024-12-11T15:20:41Z
publishDate 2022-03-01
publisher Dove Medical Press
record_format Article
series Open Access Rheumatology: Research and Reviews
spelling doaj.art-3f1b627555af414391bc8470c1b114512022-12-22T01:00:23ZengDove Medical PressOpen Access Rheumatology: Research and Reviews1179-156X2022-03-01Volume 14253873700Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World StudySicras-Mainar ATornero-Tornero JCVargas-Negrín FLizarraga ISicras-Navarro ARejas-Gutierrez JAntoni Sicras-Mainar,1 Juan Carlos Tornero-Tornero,2 Francisco Vargas-Negrín,3 Isabel Lizarraga,4 Aram Sicras-Navarro,1 Javier Rejas-Gutierrez5 1Health Economics and Outcomes Research Department, Atrys Health, Barcelona, Spain; 2Department of Anesthesiology, Hospital Clínico Universitario of Valencia, Valencia, Spain; 3Healthcare Center Dr. Guigou, Canary Islands Health Service, Tenerife, Spain; 4Medical Department, Pfizer, SLU, Alcobendas, Madrid, Spain; 5Health Economics and Outcomes Research Department, Pfizer, SLU, Alcobendas, Madrid, SpainCorrespondence: Antoni Sicras-Mainar, Health Economics and Outcomes Research Department, Atrys Health, C/ Provença 392, bajos, Barcelona, 08025, Spain, Tel +34 934 581 561, Fax +34 93 458 73 03, Email ansicras@atryshealth.comPurpose: To estimate the number of sick leave days and productivity costs in active workers with osteoarthritis (OA) who initiated opioid treatment for moderate/severe chronic pain in clinical practice in Spain.Patients and Methods: This is a secondary analysis of the longitudinal, retrospective OPIOIDS study, using electronic medical records (EMR) of patients aged ≥ 18 years, who started an opioid treatment for moderate/severe chronic OA pain between 2010 and 2015 after treatment failure with ≥ 1 first-line drugs (acetaminophen, metamizole and/or nonsteroidal anti-inflammatory drugs [NSAIDs]). The number of days of sick leave and productivity costs were analyzed during a follow-up period of 36 months.Results: A total of 5089 patients with moderate/severe chronic OA pain, aged 56.8 years (standard deviation [SD]: 4.6) (56.6% were female), were analyzed: 73.3% of them started a treatment with weak opioids and 26.7% of them were treated with strong opioids. At 36 months, adherence was 21.0% (strong opioids: 15.4%; weak opioids: 23.0%; p< 0.001), and 77% of patients had at least one sick leave related with chronic OA pain, with an average of 93 days off work in all working patients (120.5 days in patients with sick leaves). Besides, 16.9% of the study population had sick leave periods that lasted at least 6 months. Pain reduction was modest (− 1.2 points; − 4.0%, p< 0.001). The cost of sick leave was € 2594 patient/year, and factors such as older age (β=0.043), female sex (β=0.036), comorbidities (β=0.035) and strong opioid use (β=0.031) were associated with higher productivity costs (p< 0.05 in all associations).Conclusion: Active workers who started opioid treatment for moderate/severe chronic OA pain showed an increased frequency of sick leave and productivity cost, with a modest effect on pain relief. Older age, female sex, comorbidities, and strong opioids were associated with higher costs for society.Keywords: analgesics, arthritis, disability, sick days, observational studyhttps://www.dovepress.com/sick-leave-and-costs-in-active-workers-with-chronic-osteoarthritis-pai-peer-reviewed-fulltext-article-OARRRanalgesicsarthritisdisabilitysick daysobservational study.
spellingShingle Sicras-Mainar A
Tornero-Tornero JC
Vargas-Negrín F
Lizarraga I
Sicras-Navarro A
Rejas-Gutierrez J
Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
Open Access Rheumatology: Research and Reviews
analgesics
arthritis
disability
sick days
observational study.
title Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_full Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_fullStr Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_full_unstemmed Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_short Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
title_sort sick leave and costs in active workers with chronic osteoarthritis pain in spain outcomes of the opioids real world study
topic analgesics
arthritis
disability
sick days
observational study.
url https://www.dovepress.com/sick-leave-and-costs-in-active-workers-with-chronic-osteoarthritis-pai-peer-reviewed-fulltext-article-OARRR
work_keys_str_mv AT sicrasmainara sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT tornerotornerojc sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT vargasnegrinf sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT lizarragai sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT sicrasnavarroa sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy
AT rejasgutierrezj sickleaveandcostsinactiveworkerswithchronicosteoarthritispaininspainoutcomesoftheopioidsrealworldstudy